Evogene Ltd EVGN

Morningstar Rating
$0.42 +0.02 (4.93%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EVGN is trading at a LOCK|G>pV? premium.
Price
$0.42
Fair Value
LOCK|>@#CwM!
Uncertainty
LOCK|c$ nV>?
1-Star Price
LOCK|K>c%&Y
5-Star Price
LOCK|!jVPHc
Economic Moat
LOCK|MN%<
Capital Allocation
—

News

Trading Information

Previous Close Price
$0.40
Day Range
$0.39–0.44
52-Week Range
$0.35–1.50
Bid/Ask
$0.39 / $0.42
Shares Outstanding
15.80M
Market Cap
$6.70M
Volume/Avg
625,233 / 2M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
3.21
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
52

Valuation

Metric
EVGN
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
3.21
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
EVGN
Quick Ratio
3.43
Current Ratio
3.57
Interest Coverage
−4.16
Quick Ratio
EVGN

Profitability

Metric
EVGN
Return on Assets (Normalized)
−68.16%
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
−87.41%
Return on Assets
EVGN

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|C!#<p%BLOCK|H!mPj$127B
Regeneron Pharmaceuticals Inc
REGN
LOCK|np%B$KLOCK|t%<v$76B
Moderna Inc
MRNA
LOCK|@VJDY&%LOCK|Q&<$75B
argenx SE ADR
ARGX
LOCK|RDpH%H^LOCK|zQ$57B
BeOne Medicines Ltd ADR
ONC
LOCK|^@rQbvKLOCK|%rg$43B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|#!B<KcLOCK|N$JCV$30B
Royalty Pharma PLC Class A
RPRX
LOCK|nDwNs>&LOCK|mT&R$25B
BioNTech SE ADR
BNTX
LOCK|m^&rPkLOCK|>F$24B
Incyte Corp
INCY
LOCK|cs$?>ZLOCK|lrW$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|!FMMJ>LOCK|bX$15B

Sponsor Center